CellSource Co

CellSource Co Net Change in Cash

The Net Change in Cash of CellSource Co (4880.T) as of Nov 20, 2026 is 390.91 M JPY. In the previous year, Net Change in Cash was -460.11 M JPY — a change of -184.96% (higher).

Net Change in Cash

390.91 MJPY

YoY

-184.96%

Last updated:

Net Change in Cash of CellSource Co is 2025 390.91 M JPY. Net Change in Cash of CellSource Co was 2024 -460.11 M JPY. It decreases by -184.96% higher compared to the previous year.

The CellSource Co Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
123.24 M JPY
Jan 1, 2019
1.08 B JPY
Jan 1, 2020
423.46 M JPY
Jan 1, 2021
652.31 M JPY
Jan 1, 2022
714.26 M JPY
Jan 1, 2023
1.66 B JPY
Jan 1, 2024
-460.11 M JPY
Jan 1, 2025
390.91 M JPY
The CellSource Co Net Change in Cash history
YEARNet Change in CashYoY
390.91 MJPY-184.96%
-460.11 MJPY-127.76%
1.66 BJPY+132.05%
714.26 MJPY+9.50%
652.31 MJPY+54.04%
423.46 MJPY-60.81%
1.08 BJPY+776.81%
123.24 MJPY+45.98%
84.43 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

Net Change in Cash of CellSource Co is 390.91 M JPY in 2025.

Net Change in Cash of CellSource Co changed from -460.11 M JPY to 390.91 M JPY, representing a -184.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash CellSource Co since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's CellSource Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — CellSource Co

All Key Metrics — CellSource Co